Pelthos Therapeutics Inc.

PTHS NYSE CIK: 0001919246

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Emerging growth company
State of Incorporation NV
Business Address 4020 STIRRUP CREEK DRIVE, DURHAM, NC, 27703
Mailing Address 4020 STIRRUP CREEK DRIVE, DURHAM, NC, 27703
Phone 919-908-2422
Fiscal Year End 1231
EIN 863335449

Recent SEC Filings

Form Type Date Filed Document
4/A Insider transaction amendment April 1, 2026 View on SEC
4/A Insider transaction amendment April 1, 2026 View on SEC
4/A Insider transaction amendment April 1, 2026 View on SEC
4/A Insider transaction amendment April 1, 2026 View on SEC
4/A Insider transaction amendment April 1, 2026 View on SEC
4/A Insider transaction amendment April 1, 2026 View on SEC
4/A Insider transaction amendment April 1, 2026 View on SEC
4/A Insider transaction amendment April 1, 2026 View on SEC
4/A Insider transaction amendment April 1, 2026 View on SEC
8-K Current report of material events March 19, 2026 View on SEC

Annual Reports

10-K March 19, 2026
  • Successfully completed IPO in February 2024, becoming a public company and securing significant capital.
  • Rapidly expanded its dermatology product line through strategic acquisitions, including Xepi and XEGLYZE assets.
View Analysis

Material Events

8-K Strategy Change January 12, 2026
Low Impact
  • Pelthos adjusted director compensation to align with peer group standards.
  • The changes aim to attract and retain highly skilled and engaged non-employee directors.
View Analysis
8-K Acquisition January 2, 2026
High Impact
  • Pelthos Therapeutics Inc. acquired Xeglyze, a head lice treatment, and all related assets from Hatchtech Pty Ltd.
  • The acquisition includes all rights, patents, trademarks, technical knowledge, regulatory approvals, inventory, and equipment for Xeglyze.
View Analysis

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.